Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +15189.21% | +6798.46% | +92.73% | +15.20% | +17.74% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +252.61% | +565.33% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +19.12% | +21.28% | +17.45% | +20.04% | +33.48% |
| Weighted Average Shares Diluted Growth | +19.12% | +21.28% | +17.45% | +20.04% | +33.48% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +45820.53% | +30215.38% | +89.65% | +19.71% | +18.90% |
| Inventory Growth | +396.72% | +272.06% | +78.91% | +34.04% | +0.31% |
| Asset Growth | +16.67% | +11.14% | -5.90% | -8.69% | +0.30% |
| Book Value per Share Growth | +2.01% | -6.89% | -22.62% | -24.36% | -26.33% |
| Debt Growth | -23.20% | -36.33% | -34.91% | -33.50% | -16.85% |
| R&D Expense Growth | -17.43% | -3.64% | +27.83% | +10.15% | -4.67% |
| SG&A Expenses Growth | +42.14% | +68.17% | +10.26% | -12.64% | -14.96% |